Last reviewed · How we verify
18F-PSMA
18F-PSMA is a fluorine-18 labeled radiotracer that binds to prostate-specific membrane antigen (PSMA) for positron emission tomography (PET) imaging of PSMA-expressing tumors.
18F-PSMA is a fluorine-18 labeled radiotracer that binds to prostate-specific membrane antigen (PSMA) for positron emission tomography (PET) imaging of PSMA-expressing tumors. Used for PET imaging of PSMA-positive prostate cancer, Detection and staging of metastatic prostate cancer.
At a glance
| Generic name | 18F-PSMA |
|---|---|
| Also known as | 18F-DCFPyL Injection |
| Sponsor | Alessandro D'Agnolo |
| Drug class | PET imaging agent / Radiotracer |
| Target | PSMA (Prostate-Specific Membrane Antigen) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
18F-PSMA targets PSMA, a transmembrane glycoprotein highly expressed on prostate cancer cells and certain other malignancies. The fluorine-18 radiolabel enables PET imaging to visualize and localize PSMA-positive lesions, facilitating tumor detection, staging, and treatment planning. This diagnostic imaging agent helps clinicians identify metastatic disease and guide therapeutic decisions.
Approved indications
- PET imaging of PSMA-positive prostate cancer
- Detection and staging of metastatic prostate cancer
Common side effects
Key clinical trials
- High Resolution, 18F-PSMA PET-MRI Before Prostate Cancer HIFU or Radical Prostatectomy (PHASE2)
- Optimizing Timing of rhPSMA-7.3 (18F) for Assessing Site(s) of Recurrent Disease Following Radical Prostatectomy (PHASE3)
- Focal Therapy With Stereotactic Body Radiation Therapy (SBRT) for Patients With a Single Prostate Tumor (PHASE2)
- An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC. (PHASE3)
- Utility of 18F-rhPSMA-7.3 in the Diagnosis of Prostate Cancer After Focal Gland Treatment (NA)
- 18F-PSMA PET/CT Versus CT Alone in Assessment of Prostatic Cancer Patients
- PSMA-PET: Deep Radiomic Biomarkers of Progression and Response Prediction in Prostate Cancer (PHASE3)
- Androgen Deprivation Therapy (Relugolix) for the Improvement of Diagnostic Imaging (PSMA PET/CT Scan) in Patients With High Risk or Very High Risk Prostate Cancer, The EnrichPSMA Trial (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 18F-PSMA CI brief — competitive landscape report
- 18F-PSMA updates RSS · CI watch RSS
- Alessandro D'Agnolo portfolio CI